Tumor Infiltrating Lymphocytes

BIOLOGICAL6 trials

Sponsors

Hadassah Medical Organization, National Cancer Institute (NCI), Yale University, Shanghai Juncell Therapeutics, Fujian Cancer Hospital

Conditions

Advanced Solid TumorEffects of ImmunotherapyMetastatic MelanomaSkin CancerSolid TumorTreatment Side EffectsTumor Infiltrating Lymphocytes

Early Phase 1

A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes

TerminatedNCT03526185

Yale UniversityMetastatic Melanoma

Start: 2018-02-06End: 2020-12-01Updated: 2022-07-25

A Clinical Study on TIL for the Treatment of Advanced Solid Tumors

RecruitingNCT05087745

Shanghai Juncell TherapeuticsAdvanced Solid Tumor, Effects of Immunotherapy, Treatment Side Effects +1

Start: 2021-12-10End: 2025-12-10Target: 50Updated: 2024-04-17

TIL Cells for the Treatment of the Advanced Solid Tumors Patients

Not yet recruitingNCT05649618

Fujian Cancer HospitalSolid Tumor

Start: 2022-12-05End: 2026-03-31Target: 42Updated: 2022-12-14

Phase 1

Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic Melanoma

TerminatedNCT01369888

National Cancer Institute (NCI)Metastatic Melanoma, Skin Cancer

Start: 2011-05-31End: 2014-05-31Updated: 2015-01-27

Phase 2

Treatment of Metastatic Melanoma With Tumor Infiltrating Lymphocytes and IL-2 Following Lympho-depleting Chemotherapy

Hadassah Medical OrganizationMetastatic Melanoma

Start: 2008-07-31End: 2020-07-31Target: 20Updated: 2018-09-18

Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma

TerminatedNCT01369875

National Cancer Institute (NCI)Metastatic Melanoma, Skin Cancer

Start: 2011-06-17End: 2012-02-14Updated: 2019-12-10